Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

Life sciences firm to take part in Dundee University hepatitis C trial

Dundee University's School of Medicine.
Dundee University's School of Medicine.

AIM-listed molecular diagnostics firm Genedrive will participate in a hepatitis C study led by Dundee University.

Manchester-based Genedrive produces an assay that can diagnose hepatitis C (HCV) within 90 minutes.

The multi-centre trial will assess the impact of out-reach hepatitis C diagnostics and therapy in a pharmacy setting versus commercial treatments.

Funded by pharmaceutical firm AbbVie, the study will be led by John Dillon, professor of hepatology and gastroenterology at the university.

It will cover up to 40 pharmacies across three sites in Scotland, Wales, and Australia. The study is expected to enrol approximately 140 patients over two years.

David Budd, chief executive of Genedrive, said: “The advancement of molecular diagnostics to the point of need will provide faster treatment decisions to patients who have difficulty accessing traditional centralised services.

“We see the requirement for test and treat outside of centralised services as a common theme across our menu targets.


>> Keep up to date with the latest news with The Courier newsletter


“We are very pleased to be working with Professor Dillon in further proving the cost effectiveness and clinical benefits of Genedrive HCV-ID in another near patient setting.”

The study will focus on people undergoing opiate substitute therapy and determine if more people with hepatitis C can be treated and cured.

Mr Dillon said: “I am delighted that this study is now starting. It is vital that if we are to eliminate HCV, we must find novel ways of using paradigm shifting technology like Genedrive HCV-ID in care pathways, to bring cure of HCV to the people who need it most.”

Genedrive’s HCV test has been launched in Africa and Asia and has a distribution agreement in place in India.

The company also has tests in development for tuberculosis and antibiotic induced hearing loss.